newsfilter
← Latest News
Business Wire·

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701, bringing the total